Please ensure Javascript is enabled for purposes of website accessibility

China grants patent for EntreMed drug

EntreMed Inc., a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, announced it has received a patent from the Chinese State Intellectual Property Office for ENMD-2076, its lead drug candidate.

ENMD-2076 has completed Phase 1 clinical trials in solid tumor cancers, leukemia and multiple myeloma, and is completing a Phase 2 trial for ovarian cancer.

Other Phase 2 clinical trials are currently enrolling breast-cancer patients at hospitals in Colorado and Indiana, and Toronto, Canada.

EntreMed is based in Rockville and has local operations in Beijing, China.